ArticleRSC advances2026
Synergistic beeswax-based nano-formulation for enhanced chronic wound healing and antibacterial potency.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beeswax in Pharmaceutical Sciences: A Comprehensive Review of Its Chemical Composition, Functional Applications, Types, and Formulation Roles.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic wounds, affecting over 10.5 million U.S. Medicare beneficiaries and exacerbated by diabetes, represent a critical healthcare challenge due to multifactorial pathophysiology, antimicrobial resistance, and inadequate therapeutic delivery. To address these limitations, we developed a novel beeswax-encapsulated emulsified formulation (F4) combining delafloxacin (DLX), lidocaine (LIDO), and sodium hyaluronate (SHA). F4 demonstrated high encapsulation efficiency (87.6-91.3%), optimal nanoparticle characteristics (115.68 nm, PDI 0.26, zeta potential -31.70 mV), and pH-responsive sustained release (94-100% cumulative release at 24 h, pH 7.4). Kinetic modeling confirmed a diffusion-controlled release mechanism (Korsmeyer-Peppas
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.